The Qatar Ministry of Public Health has approved Endari (L-glutamine) to treat adults and children, starting at age 5, with sickle cell disease (SCD), the therapy’s developer, Emmaus Life Sciences, announced.
“We are grateful that Qatari officials made access to Endari easier for the sickle cell patients in the country,” Yutaka Niihara, MD, chairman and CEO of Emmaus, said in a press release.
Recommended Reading
…
…
